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Abstract
ENANTIOMERIC INFLUENCES IN NEUROLEPTIC BINDING TO 
MODELS OF THE DOPAMINE RECEPTOR
by
Timothy A. Robert
Various in vitro models are believed to represent a 
physiologically relevant dopaminergic component of schizo­
phrenia. Neuroleptic agents competitively inhibit both 
dopamine-sensitive adenylate cyclase (DA/AC) and radiolabeled 
agonist or antagonist binding In neuronal homogenates. The 
effects of a few dopamine antagonists have been shown to be 
stereospecific in vivo and in vitro. Experiments were under­
taken to further examine the in vitro dopaminergic effects 
of optically active phenothiazTne derivatives. Such studies 
were also intended to help clarify the relationship between 
DA/AC, 3H-dopamine binding (3H-DA), and 3H-spiroperidol. 
(3H-SP) binding.
Binding studies were performed in calf caudate nucleus 
homogenates with (+) and (-) methotrimeprazine, (+) and (-) 
thioridazine, (+) and (+) promethazine, (+) and (-) dioxo- 
promethazine, and (+) and (-) P-892. Various concentrations 
were examined for their ability to compete with 5nM 3H~DA or
0.15nM 3H-SP binding. In addition, (+) and (-) methotrimep- 
razine isomers were evaluated in the DA/AC assay. Rat caud­
ate nuclei were pooled and homogenized in the studies of 
methotrimeprazine inhibition of DA/AC cyclic adenosine 3',5* 
monophosphate (cAMP) production. Enzyme activity was esti­
mated by measuring, via radioimmunoassay, pmol cAMP produced/ 
mg protein/minute.
It was observed that there was a significant (P<0.05, 
analysis of variance) isomeric effect only for the neuro­
leptics, thioridazine and methotrimeprazine, in displacing 
3H-DA wheras 3H-SP competition exhibited stereospecificity 
with promethazine and dioxoproraethazine as well. Isomer 
pairs differed in their magnitudes of stereospecificity 
(ratio of 50% inhibitory concentrations of (+) and (-) iso­
mers) between 3H-DA and 3H-SP displacement. In marked con­
trast to the radioligand binding results, DA/AC failed to 
exhibit an isomeric effect upon inhibition with methotrimep­
razine.
These observations suggest that the binding sites for 
dopamine agonists and antagonists associated with these in 
vitro models are all different molecular species.
iii.
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PREFACE
The necessary counterpart of any neurotransmitter is its 
receptor located upon the target cell. Receptors themselves 
are responsible for transduction of the chemical message to 
an initial physiological effect. Many theoretical models of 
receptors have been proposed (Triggle, '78) over the years 
to account for the observed effects of transmitters and drugs 
upon their receptive structures. A theory developed by
A.J. Clark early in the 1920's remains the cornerstone of 
receptor models. While the features of various models such 
as occupation theory, receptor reserve, or rate theory may be 
different, there remains the common element of drug/receptor 
interaction. An essential first step in this process is the 
recognition between chemical mediator and the receptive 
structure. This biochemical interaction is fundamentally 
determined by structural compatability of the transmitter and 
its recognition site. The process of recognition is based 
upon chemical and stereochemical parameters which are crucial 
determinants of both transmitter and drug action at the 
molecular level. Stereoisomers of efficacious agents with 
even the most subtle differences in configuration are 
differentiable by their receptors. It was the purpose of the 
experiments described herein to examine the stereospecificity 
of antagonistic molecular interactions with a representative 
central nervous system dopamine receptor.
TABLE OF CONTENTS
APPROVAL..................................................ii
ABSTRACT.......................................... , . . .iii
ACKNOWLEDGMENTS...................................... .. . iv
PREFACE.....................................................v
LIST OF T A B L E S ........................................... ix
LIST OF FIGURES............................................ x
I. INTRODUCTION ........................................  I
A. In Vivo Studies.................................... I
B. In Vitro Studies..................................3
C. Problems in Receptor Models....................... 6
D. Objectives........................................ 8
E. Hypothesis....................................... 12
II. Experimental ........................................  15
A. Materials.  ...............................15
1, Chemistry..................................... 15
2. Pharmacology ................................. 16
a. Binding Studies........................... 16
b. Enzyme Studies ...........................17
B. Methods........................................... 18
1. Chemistry..................................... 18
a. Synthesis of Optically Active P-892. . .18
b. Resolution of Dioxopromethazine..........21
c . Resolution of Thioridazine .............  23
d. General Chemical Methods ................ 24
vi.
2. Pharmacology.......................   24
a. Binding Studies........................ 24
i. 3H-Dopamine Binding Experiments. .27
ii. 3H-Spiroperidol Binding Experiments. . 28
b. Dopamine-sensitive Adenyl Cyclase
Experiments...................... 28
c. General Pharmacological Methods. . . .  31
III. RESULTS............................................ 32
A. Chemistry......................................32
1. Structural Verification of P-892 . . . .  32
2. Verification of Isomeric Resolution. . . 32
B. Pharmacology................................. 37
1. Binding Studies.  .................. 37
a. General Results..............   37
b. 3 H-Dopamine...................... 37
c. 3 H-Spiroperidol.................. 48
2. Enzyme Studies......................... 51
IV. DISCUSSION........................................61
A. Chemistry......................................61
B. Pharmacology................................. 63
a. General Considerations .................  63
i. Saturation Studies .................  63
ii. Competition Studies................ 64
b. 3H-Dopamine Binding Competition........ 68
c. 3H-Spiroperidol Binding Competition. . . 68
d. Isomeric Drug Effects...................70
vii.
2. Enzyme Assay   71
3. Implications for Further Research, . . . .  72
a. Binding Studies....................   . 72
b, Enzyme Studies..........   74
BIBLIOGRAPHY .......................................  75
V I T A ................................................. 82
viii.
LIST OF TABLES
Table Page
1. PHYSICAL PROPERTIES OF P-892 ................. 33
2. OPTICAL ACTIVITY OF RESOLVED PHENOTHIAZINES. . 36
3. RADIOLABELED AGONIST BINDING INHIBITION. . . . 47
4. RADIOLABELED ANTAGONIST BINDING INHIBITION . . 57
lx.
LIST OF FIGURES
Text-Figure 1. Enantiomers of methotrimeprazine.......... II
Text-Figure 2. Structures of optically active phenothi-
azine derivatives used in receptor 
studies.....................     13
Text-Figure 3. Mass spectrum of purified P-892.......... 34
Text-Figure 4. Nuclear magnetic resonance (NMR) spectrum
of purified P-892......................  35
Text-Figure 5. Thin-layer chromatogram of phenothiazine
derivatives in HC1 salt form........... 38
Text-Figure 6. Example of a 3H-DA receptor saturation
study....................................40
Text-Figure 7. Scatchard plot of a 3H-DA saturation study41
Text-Figure 8. Computer-graphic plot of 3H-DA competition
by isomeric methotrimeprazine.......... 42
Text-Figure 9. Computer-graphic plot of 3H-DA competition
by thioridazine (Mellaril).............. 43
Text-Figure 10. Computer-graphic plot of 3H-DA competi­
tion by promethazine....................44
Text-Figure 11, Computer-graphic plot of 3H-DA competi­
tion by dioxopromethazine(Frothanon)... 45
Text-Figure 12. Computer-graphic plot of 3H-DA competi­
tion by P-892. . .  ......................  46
Text-Figure 13. Example of 3H-SP receptor saturation
study....................................49
Text-Figure 14. Scatchard plot of 3H-SP saturation study 50
Text-Figure 15. Computer-graphic plot of 3H-SF competi­
tion by isomeric metnotriraeprazine 52
Text-Figure 16. Computer-graphic plot of 3H-SP competi­
tion by isomeric thioridazine(Mellaril) 53
Text-Figure 17. Computer-graphic plot of 3H-SP competi­
tion by promethazine.................  54
Text-Figure 18. Computer-graphic plot of 3H-SP competi­
tion by dioxopromethazine(Prothanon)... 55
Text-Figure 19. Computer-graphic plot of 3H-SP competi­
tion by P-892........................... 56
Text-Figure 20. Inhibition of dopamine-stimulated adenyl
cyclase activity by methotrimeprazine 
optical isomers......................... 59
xi.
1I . INTRODUCTION
A. In Vivo Studies
The compound, 3 ,4-dihydroxyphenylethylamine, commonly 
referred Co as dopamine (DA), has been Implicated as a 
neurotransmitter in diverse tissues in many species (Cooper 
et al. , '74; Goldberg et^  al. , *78). In peripheral tissues 
of higher animals, this compound is not found alone in 
their innervating neurons (Horn, *75). Indeed, the 
mechanism of specific dopaminergic actions in renal, mesen­
teric, coronary, and cerebral vascular beds may be con­
founded by interactions with other adrenergic receptors.
The renal preparation studied by Goldberg et.al..('78) is 
suggestive of significant differences between these peri­
pheral receptors and others such as those in the central 
nervous system (CNS).
It is possible that DA serves a more specialized func­
tion in the CNS of mammals. Indeed, it probably serves as 
a direct mediator of chemical transmission. The diverse 
central functions are all very important determinants of 
mammalian well-being, and the role of DA as a neurotrans­
mitter in the CNS appears to be quite complex (Seeman et al^ . , 
’78). Functional abnormalities in DA systems are implicated 
as being vitally important in determining such disease states 
as Parkinsonism (Ehringer and Hornykiewicz, '60) and schizo­
phrenia (Snyder, *76). These two disease states are believed
to be the result of diminished dopaminergic function in the 
basal ganglia and pathologically increased activity in an 
unidentified brain region, respectively. The dopamine 
hypothesis of schizophrenia is the most generally accepted 
model of this disease. Presumably, a population of neurons 
exists that receives excessive dopaminergic input. Neuro­
leptics act as antipsychotic agents by blocking the post- 
synaptic receptors (Aghajanian and Bunney, ’74) experiencing 
this superfluous DA exposure. Additionally, dopaminergic 
mechanisms are involved in such identified functions as 
modulation of prolactin release (Caron et al., *78) and the 
emetic response of the medullary chemoreceptor trigger zone. 
Elucidation of the molecular mechanisms whereby DA produces 
its effects may prove to be a valuable asset to clarifying 
and understanding the role of DA in normal and pathological 
states.
Prior to the early seventies, DA mechanisms were studied 
exclusively in vivo. Early conclusions regarding the role 
of DA in the CNS were generally based upon whole animal 
experiments in which behavioral parameters were observed. 
These experiments were often difficult to interpret (Dankova 
et al., *78) due in large extent to the fact that multiple 
neuronal systems may potentially interact (Breese et al., 
*78). The possibility of involvement of non-DA utilizing 
neurons cannot be ruled out.
The questions of drug distribution and metabolism are
of real concern with in vivo models, Compounding these 
problems is the question of innate pharmacological specifi­
city of the agents undergoing evaluation. These potentially 
confounding factors made in vivo models difficult to use in 
investigations of DA molecular mechanisms. Even so, in 
vivo studies of the behavioral and neurophysiological effects 
of dopaminergic systems (Van Rossum, '78) have suggested 
the existence of at least two types of receptors.
B. In Vitro Models
The advent of in vitro models of dopaminergic systems 
has allowed more discrete examination of the biochemical 
pharmacological interactions between DA and its receptors. 
While these in vitro models have refined the tests of DA 
function, they have by no means produced explicit under­
standing of these receptors. The first model of a CNS 
dopaminergic system identified and isolated was the 
dopamine-stimulated adenylate cyclase (DA/AC) of the rat 
neostriatum, a tissue rich in endogenous DA and adenylate 
cyclase. Kebabian et al. ( !72) reported that the enzymatic 
activity of adenylate cyclase, catalysing the hydrolysis 
and cyclization of adenosine 5'-triphosphate (ATP) to 
adenosine 3',5'-cyclic monophosphate (cAMP), was increased 
as a function of DA concentration. The hypothesis was 
presented by these authors that the DA-sensitive adenylate 
cyclase was the putative DA receptor. Subsequently, evidence 
was presented that this DA-sensitive enzyme was the site of
action of antipsychotic drugs (Clement-Cormier et_ al. t '74JL.
There is a significant discrepancy between the clinical 
potency of one class of antipsychotic drugs and its ability 
to inhibit DA/AC activity. The butyrophenones, such as 
haloperidol, are very potent in vivo, yet are weaker in 
vitro inhibitors of DA/AC. Since these early papers,
DA/AC has been detected in many brain regions responsive 
to DA, with the notable exception of the anterior pituitary 
gland (Schmidt and Hill, *77). The absence of demonstrable 
DA/AC in anterior pituitary has also cast a degree of un­
certainty upon the concept of this enzyme being the DA 
receptor. Furthermore, bromocryptine, a DA agonist in vivo, 
is unable to stimulate DA/AC (Schwarcz et al., * 78b).
A second type of in vitro DA receptor model developed 
as a logical outgrowth of the DA/AC paradigm. Obviously, 
if DA stimulates the enzyme, it must first interact with it 
in some fashion. It was therefore reasonable to expect a 
binding interaction, and experiments were undertaken to 
identify this phenomenon (Burt e£ al., * 75; Seeman e£ al., 
'75). Specific binding of radiolabeled DA and DA antagonists 
was observed in preparations of mammalian caudate nucleus. 
Following these initial reports, binding of radiolabeled 
agonists (Creese ejt al. , '75a; Seeman at al. , '76b; Tittler, 
et al., '77; Schwarcz et. al., *73b) and antagonists (Creese 
et al., '77;Hyttel, *78) was observed in a number of DA- 
sensitive CNS tissues (Caron at al., '78; Pedigo et al.,
*78). The binding of these drugs was observed to be compe­
titively inhibited by various unlabeled agonists and antago­
nists. All effective neuroleptics were shown to function 
as antagonists in their ability to inhibit radioligand 
binding. Inhibition was observed to be proportional to 
in vivo efficacy (Creese et al., '76). The correlation 
between in vitro binding inhibition and clinically admini­
stered doses of antipsychotic drugs is extremely good.
This relationship also holds for the butyrophenones which, 
as a group, departed from predicted behavior with DA/AC.
In addition, it was observed in very early experiments that 
the dopamine receptor exhibited different properties, de­
pending on whether an agonist or antagonist was being dis­
placed (Creese et al., ’75b).
The fact that agonists were better at displacing agonists 
compared to antagonists, while the converse was true for 
antagonists, encouraged Creese et: al. ( ’75b) to posit a 
two-state receptor model. It was proposed that the DA 
receptor existed in two rapidly interconvertible conforms-* 
tions. The presence of either an agonist or antagonist 
was envisioned to induce the receptor to accomodate that 
class of drug and therefore exchange more readily with a 
similar class of competitor. It was considered unlikely 
that two distinct receptive structures were involved in 
determining the difference between agonist and antagonist 
displacement since' the total number and brain tissue dis­
tribution (Leysen and Laduron, r77) of these binding sites 
were approximately equal.
C. Problems In Receptor Models
It is readily apparent that, while these in vitro models 
of dopaminergic systems have clarified questions of specific 
drug effects, many mechanistic questions remain or, indeed, 
have been produced. Two obvious questions pertain to the 
relationship between the receptors undergoing measure­
ment in these assays. First, what are the relationships be­
tween DA/AC and the radioligand binding site and, secondly, 
what is the exact relationship between the agonist and 
antagonist receptive structures? Answers to these questions 
have proved to be elusive, but very recently some experi­
mental evidence has been accummulating to support some 
tentative conclusions (Kebabian and Caine, *79).
Evidence regarding receptor non-identity or multiple 
receptors has largely been anatomical, pharmacological, and 
biochemical in nature. It has been observed In ultracen­
trifugation fractionation experiments that the subcellular 
distribution of DA/AC and the antagonist binding site are 
somewhat different in the rat striatum (Clement-Cormier and 
George, *78). Another source of evidence suggesting recep­
tor differences is that if cell bodies in the striatum are 
chemically lesioned with kainic acid, DA/AC activity is 
rapidly lost, while 507» of the total radio-antagonist 
binding sites remain (Schwarcz et al,, '78a). Kainic acid
is a glutamic acid analog that selectively destroys cell 
soma while leaving cellular processes such as axons intact. 
Residual binding after kainate lesioning (507o) is largely 
eliminated following cortical ablation and this observation 
is suggestive of a presynaptic binding site since the 
cortex is a site of afferent innervation to the basal 
ganglia. A third line of evidence is that differences 
are noted in pharmacological properties of the receptors 
when the actions of dopaminergic ergots such as bromo- 
cryptine and lergotrile are examined. These are potent 
dopamine agonists at the anterior pituitary and compete with 
specific agonist binding, yet they act as DA/AC antagonists 
in the striatum (Kebabian and Caine, *79). After kainic 
acid lesions in the striatum have been produced, sensiti­
vity of radioligand binding to guanine triphosphate (GTP) 
is lost (Creese et al., *79). Since guanine nucleotides 
supposedly regulate binding in association with adenylate 
cyclase, the binding of radiolabeled agonists and antagonists 
is believed to occur at one site coupled to adenylate 
cyclase and one which is not. In light of this evidence, 
it appears that there are at least two forms of receptors 
for dopamine. Based upon these indirect observations, the 
DA/AC receptor complex is apparently not identical to the 
radioligand receptor.
The question pertaining to the nature of radioligand 
binding sites persists. What is the nature of the relation-
ship between the agonist and antagonist binding sites? 
Analysis of this problem by the usual biological techniques 
has proven to be difficult. A mathematical analysis of 
binding data has suggested that a model involving two 
distinct sites may best fit observed effects (Beld et al^, 
’78). Indeed, Creese et al. (_ '79), who originally proposed 
the two-state model, now suggest that labeled agonists and 
antagonists bind to distinct states of DA/AC dopamine 
receptors. This postulate is based on their observation 
that agonist binding site drug-specificity resembles most 
closely that of the DA/AC.
D. Obj ectives
It appears that binding sites may be both coupled to 
DA/AC and not coupled. Regardless of the degree of indepen­
dence between DA/AC and radioligand binding sites, there 
remain at least two questions of potential importance. Is 
the receptive structure of DA/AC for dopamine and/or its 
antagonists the same molecular entity as that involved in 
agonist or antagonist binding sutdies? Also, what is the 
chemical relationship between the agonist and antagonist 
binding sites? Answers to these questions were the objec­
tives of a series of experiments which will be described 
in the following text.
An attempt to characterize the molecular properties of 
the DA recognition site was undertaken through the use of 
a specialized group of pharmacological probes. It was
theorized that a competitive antagonist with some structural 
elements common to the dopamine molecule would possess en­
hanced selectivity in its dopaminergic effects. There is 
evidence (Horn and Snyder, '71 ; Feinberg and Snyder, *75) 
that the prototype neuroleptic phenothiazine derivative, 
chlorpromazine, does have a favored conformation that struc­
turally mimics the dopamine molecule. Many phenothiazine 
derivatives with differing neuroleptic potencies have been 
synthesized through the years and they all have structural 
elements similar to DA. Several structure-activity re­
lationships for the antischizophrenic action of phenothiazine 
derivatives have been well characterized (Gordon et al.,
’63). It is known that, for maximum activity, a three- 
carbon chain between the 10-N of phenothiazine and its 
terminal amino functionality is optimal. If this aliphatic 
moiety bears a side-chain or other functionality, activity 
is generally reduced. However, if a substituent is located 
upon a carbon atom in this chain, an asymmetric center is 
formed imparting to the molecule, The effects of optical 
isomerism within the 10-N substituent have not been analyzed 
in any systematic or comprehensive fashion (Ferris at al.,
’76) .
Previous reports have suggested a stereospecific nature 
of the DA receptor in vivo (Gordon et al., *63; Nielsen 
et al. , * 73; Humber et al_. , * 75 ; Remy at al. , ' 77) as well 
as in vitro (Burt et al., '76; Seeman et al., *76a). These
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stereospecific effects of antagonists are seen with. both, 
optical and geometric isomers, tt is well known that opti­
cal isomers have identical chemical properties (with achiral 
moieties) whereas geometric iosmers do not. Because optical 
isomers exist in two discrete configurations, they can 
influence receptors solely upon the basis of their fit to 
the receptor (Text-Fig. 1). Therefore, this class of com­
pounds was envisioned as uniquely suitable for studying 
the chemical properties of the DA. receptor.
Therefore, the experiments were undertaken to assess 
specifically the stereospecificity of the DA recognition 
site in various models of dopaminergic systems. In vitro 
models of DA/AC and 3Il-agonist and 3H-antagonist binding 
were examined with selected optically active phenothiazine 
derivatives. Some of these optically active compounds 
have been used clinically. These useful drugs include 
thioridazine (Mellaril), methotrimeprazine (Levoprome), 
promethazine (Phenergan), and dioxopromethazine (Prothanon). 
Promethazine and dioxopromethazine are not useful as neuro­
leptics but do have antimetic and antihistaminic properties 
due in part to their two-carbon aliphatic side chains 
(Gordon et al., ’63). Besides these clinically employed 
drugs, there are many experimental optically active 
phenothiazine derivatives which have not been approved for 
use in humans (Usdin and Efron, '72). Nevertheless, these 
compounds are of pharmacological interest and are suitable
11
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Text-Fig. 1. Enantioraers of methotrimeprazine. Each isomer 
is shown in the favored conformation of pheno­
thiazine neuroleptics with the dopamine molecule 
(dashed figure) superimposed. In the trans-g- 
rotamer conformation, dopamine exhibits several 
structural elements in common with methotrimep­
razine. It can be seen that the optical isomers 
differ in their ability to approximate the 
hydrophobic ethylene region in dopamine.
12
for use In vitro. One such optically active compound was 
selected for use in these experiments because of its pur­
ported unusual properties. Usdin and Efron (. '72) classified 
P-892 as a CNS excitant, an unusual property for a pheno­
thiazine derivative. Employing thioridazine, metho­
trimeprazine, promethazine, dioxopromethazine, and P-892 
isomers for investigations upon the DA receptor in vitro 
was envisioned as providing a spectrum of affinities at the 
recognition site with a wide range of chemical structures 
(.Text-Fig. 2). Methotrimeprazine and thioridazine both 
possess the optimum three-carbon segment in their side- 
chain and as a group would be predictably potent DA antago­
nists (Gordon et al., *63). In contrast, promethazine, 
dioxopromethazine, and P-892 would be expected to function 
poorly at displacing dopaminergic ligands.
E. Hypothesis
If striatal DA/AC and the DA recognition sites were 
identical, the relative difference in potency of isomeric 
antagonists In the two systems would be the same. One 
would predict no difference in ratios of response between 
the more active and less active enantiomers. Furthermore, 
if the previously observed differences between agonist and 
antagonist binding displacement ( C r e e s e  e£ al., *75b) were 
due to inherent differences in the nature of these drugs 
rather than differentiation at two receptors, optical 
isomeric effects again would be equal. If phenothiazines
13
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Text-Fig. 2. Structures of optically active phenothiazine 
derivatives used in receptor studies. Each 
compound has a single asymetric carbon atom 
which is designated with an asterisk.
cannot distinguish between receptors CKebabian and Caine, 
'79) even in their isomeric forms, it would suggest that 
the recognition sites are identical.
II. EXPERIMENTAL
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A. Materials
1. Chemis try
All drugs used in the following experiments, whether 
resolved { (+) or (-) > and/or racetnic (±), were originally 
obtained directly from their respective pharmaceutical 
manufacturer, with the exception of P-892. The following 
manufacturers provided the drugs ultimately utilized in 
the pharmacological investigations: Sandoz, (±)-thiorida­
zine (Mellaril)j Rhone-Poulenc, (+) and (-)-methotrimepra- 
zine; Wyeth, (+) and (±)-promethazine (Phenergan); VEB 
Arzneimittelwerk Dresden, (+)-dioxopromethazine (Prothanon). 
It was necessary to synthesize P-892 because its original 
maker, Chemische Fabrik Promonta GMBH, was unable to provide 
a sample of this phenothiazine derivative. P-892 was 
synthesized from phenothiazine and 1-methy1-2-piperidine 
methanol, both obtained from Aldrich Chemicals. The re­
solving agent uniformly employed was di-£-toluyl-d-tartaric 
acid, obtained from J.T. Baker Chemical Company. All other 
solvents and reagents utilized were commercially obtained 
ACS reagent grade or USP.
Optical rotations were measured on a Rudolph polari- 
meter and/or a Zeiss polarimeter with a one decimeter micro- 
polarimeter tube (capacity 0.55 ml). Proton NMR spectra 
were obtained from a C60H JEOL 60MHz instrument. Mass
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spectra were obtained from direct sample introduction 
into a Finnigan 4000 quadrupole instrument. Those pheno­
thiazine derivatives designated as photosensitive were 
protected from light with actinic glassware whenever possible. 
General reactions and procedures were performed with com­
mercially available glassware.
2. Pharmacology
a . Binding Studies
Calf caudate nuclei were obtained from Valley- 
dale Meat Packers, Bristol, VA, Radiolabeled drugs were 
obtained from commercial sources. Tritiated DA, with 
specific activities of 24.28 and 34.2 Ci/mmole, were pur­
chased from New England Nuclear. The specific label was 
located on the 1-ethyl carbon atom to yield {ethyl-1- 
3H(N)} dopamine. Tritiated spiroperidol (specific activity:
20 Ci/mmole) was purchased from Amersham Corporation. This 
compound was specifically labeled at the para position of 
the H-phenyl group to yield { phenyl-4(N)-3H } spiroperidol. 
Beta emissions were counted with the liquid scintilation 
cocktail, Aquasol IX, from New England Nuclear. Other 
reagents were obtained from various commercial sources. 
Specifically, pargyline HC1 and Tris buffer components 
were purchased from Sigma Chemical Company. Various salts 
and other chemicals were of ACS reagent grade. All 
solutions were prepared using distilled water. Butaclamol 
HC1 salt was the generous gift of Ayerst Laboratories.
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The following specific items of apparatus were notably 
important and therefore deserve attention. Radioactivity 
was monitored in all samples with a Beckman 9000 liquid 
scintillation counter. This unit is equipped with a micro­
processor allowing data reduction under conditions of 
uniform sample quenching. Tissues were homogenized using 
a Brinkman Polytron PT-10/35. The homogenates were processed 
in a Beckman L5-75B preparative ultracentrifuge equipped 
with a Type 30 fixed angle rotor. Millipore filter-holder 
assemblies of both the glass frit and, later, stainless 
steel support type were used. These holders contained 
Whatman GF/B filters (2,4 cm diameter) used throughout the 
binding studies.
b . Enzyme Studies
Striatal tissue used in the dopamine-stimulated 
adenylate cyclase inhibition studies was obtained from rats. 
Tissues were homogenized in a 30ml glass tissue grinding 
tube with a motor driven teflon pestle. Standard laboratory 
apparatus and supplies were used whenever applicable in the 
assay of adenyl cyclase activity.
Reagents and drugs used in the experiments were obtained 
from commercial sources. High purity adenosine 5'-tri­
phosphate (ATP) from equine muscle, theophylline, Tris 
buffer components, dopamine HC1, pargyline HC1, and ethylene- 
glycol bis^CS-amino-ethyl ether)-N-N'-tetraacetic acid (EGTA) 
were all purchased from Sigma Chemical Company. Other
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reagents required in the assay were ACS reagent grade 
from various suppliers, Cyclic 3 5 ' -^adenosine monophos­
phate (cAMP) assays were performed with radioimmunoassay 
(RIA) kits purchased from New England Nuclear. This RIA 
method is based upon the work of Steiner et al, (.*72) 
and differs from the method of Brown et al. (*72) which is 
what other investigators have used. The RIA method is an 
antibody saturation assay while that of Brown et al^ (*72) 
uses an endogenous binding protein. All centrifugation 
steps were performed in a Beckman J6 refrigerated centri­
fuge. Radioactivity from the 125I labeled cAMP tracer was 
measured with a Beckman Gamma 7000 spectrometer.
All enzyme experiments were paired with modified 3H-DA 
binding studies. Materials used in these experiments 
were those previously described in both the standard 
binding studies and/or standard enzyme methods.
B. Methods
1. Chemistry
a. Synthesis of Optically Active P-892
Technical grade (97%) phenothiazine was 
purified by vacuum sublimation (Baker and Brickman, '45).
The second required reactant, 2-chloromethyl piperidine, 
was prepared in optically active form from racemic 1-methyl-
2-piperidine methanol as follows. A 25ml aliquot of 1- 
methyl-2-piperidine methanol was vacuum distilled (86° at 
5 torr) to yield 17.5g of clear product. This alcohol was
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resolved in a fashion analogous to that used upon 1-methyl-
3-piperidine methanol for the synthesis of optically active 
thioridazine (Sandoz, Inc., *63). The primary difference 
in methodology was the necessary reduction to semi-micro 
scale reaction.
Two grams (15mmol) of the primary alcohol dissolved in 
7.3ml ethanol and 6.2g (ISmmol). di-£-toluyl-d-tartaric 
acid in 23.3ml ethanol were mixed and allowed to stand at 
room temperature. Approximately 4g (7tranol) of (-) salt 
precipitated out of solution. This material was recrystal­
lized from wet acetonitrile to yield 2.5g (Smmol) 0f pure 
white crystals. Basification with 5N NaOH and extraction 
into ether yielded approximately 0.4g (3mmol) of (-)-l- 
methyl-2-piperidine methanol. The original yellowish 
mother liquor containing the (+) isomer salt was placed in 
a freezer (approximately -20°C) overnight to facilitate 
crystallization of remaining (-) salt. When the resulting 
supernate was filtered cold, then dried by rotating its 
container in a hot (70°C) water bath with an applied vacuum 
of about 18 torr (roto-evaporated)( 2.6g (5mmol) of (+) 
salt remained. Alkalinization with 5N NaOH and extraction 
into ether yielded approximately 0.5g (4mmol) free (+)-l- 
methyl-2-piperidine methanol.
The optically active alcohols were then Converted to 
their respective alkyl chlorides by first forming HC1 salts 
by bubbling anhydrous HC1 through solutions in dry chloroform.
20
The levorotatory salt was refluxed 3hr with. 0.7g (SiranolX 
thionyl chloride, while the dextrorotatory salt was re- 
fluxed with 0.8g (6mmol). When the reaction was terminated, 
excess thionyl chloride and solvent were removed under 
vacuum. Basification with 5N NaOH and extraction into 
ether of the isomers of 2-chloromethyl-l-methyl piperidine- 
HC1 yielded 0.2g (Immol) of (-) base and 0.3g (2mmol) of 
(+) base. The low yields of 25 and 40% were primarily due 
to losses in handling the serai-micro samples.
Using these resolved alkyl chlorides, synthesis of 
optically active P-892 was readily accomplished. Two 
hundred mg (lmmol) of (-) alkyl chloride, 200mg Clmmol) 
purified phenothiazine, and 50mg (.lmmol) sodium amide 
were refluxed together for 3hr in dried m-xylene. The 
solvent was roto-evaporated and product collected on a 
micro cold-finger vacuum sublimation apparatus. Yield 
was virtually quantitative. Synthesis of the dextrorota­
tory compound was performed in like manner. A mixture of 
250mg (1.6mmol) (+) alkyl chloride, 330 mg (l.Gmmol) 
purified phenothiazine, and 66mg (1 .6mmol) sodium amide was 
refluxed 3hr in dry m-xylene. The product was extracted 
with 0.1N HC1 and this aqueous phase was basified with 
5N NaOH and counter-extracted with chloroform. The organic 
solvent was roto-evaporated to yield approximately 300mg 
(lmmol) of product.
A routine check of purity by analytical thin-layer
21
chromatography {silica gel G, with Skelly-Solv B (a light 
hydrocarbon fraction)/isopropanol (.85:15 v/v) as developing 
solvent) was performed on the optical isomers of P-892.
They were observed to contain a second component. This 
material was produced in a side reaction not described in 
references employing the same reaction scheme to produce 
very similar compounds (Fujii et al,, ’58). Apparently, 
the side reaction occurred readily, as about 40% of the net 
reaction product was comprised of this material. Prepara­
tive thin-layer chromatography with the same adsorbent 
and solvent system produced an effective separation of 
byproduct (I) from authentic P-892. Compound I was sub­
sequently shown to be a rearrangement compound with a seven- 
membered ring system and the same molecular weight as P-892. 
The identity of P-892 was verified by mass spectrometry,
NMR, and elemental analysis (Galbraith Laboratories, Inc., 
Knoxville, TN). Small portions of both P-892 isomers in 
their basic forms were subsequently converted to their re­
spective hydrochloride salts. Each base was first dissolved 
in anhydrous ether and reacted with dry HC1 to yield a pre­
cipitate of hydrochloride salt (approximately 5mg).
b. Resolution of Dioxopromethazine
Resolution of this compound is based upon a 
published technique (Wunderlich et al., f 66), The changes 
incorporated were largely due to the necessity of working 
with gram amounts rather than bulk quantities of the drug.
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Four grams of dioxopromethazine HC1 (Prothanon). ware con­
verted to the base by dissolution into 50ml 1^0 and basifi- 
cation with. 11,4ml IN KOH. The basic precipitate was then 
extracted into a mixture of 80ml ether and 20ml dichloro- 
methane. The organic extract was filtered and dried to 
yield approximately3.2g free base. Two grams (finimol) of 
this racemic base were dissolved in 66ml acetone and mixed 
with 3.34g (8mmol) di-£-toluyl-d-tartaric acid in 24.2ml 
methanol. After 2hr stirring at room temperature, the pre 
cipitate of (.-)-dioxopromethazine-£-toluyl-d-tartrate was 
filtered, yielding approximately 2.4g (3mmol) of salt. One 
gram of this C~)-dioxopromethazine salt was subsequently 
recrystallized from 400ml boiling methanol to yield 650mg 
of enriched isomer, A portion of this salt was then 
basified, extracted, and roto-evaporated to yield (-)- 
dioxopromethazine free base, from which approximately lOOmg 
of hydrochloride salt was generated by bubbling dry HC1 
gas through an anhydrous ether solution of the base.
The original mother liquor, remaining from the 
crystallization of (-) salt, contained the (+) salt. This 
solution was roto-evaporated to yield (+)-dioxopromethazine- 
di-£-toluyl-d-tartrate. The basification and extraction of 
this compound resulted in 0.9g (3mmol) (+)-dioxoprometha­
zine free base. A portion of this base was reacted with 
dry HC1 in anhydrous ether to yield approximately lOOmg 
(+)-dioxopromethazine HC1 salt.
c. Resolution of Thioridazine
This method was empirically developed, as the 
author was unable to reproduce the cryptic method which 
has previously been published CBourquin et al., ’58).
A 1.8g sample of racemic thioridazine hydrochloride was 
converted to free base by reaction with 4,4ml IN KOH and 
extracted into ether as the free base. The organic phase 
was roto-evaporated to yield thioridazine base as a 
yellow, viscous oil. Upon standing in vacuo for two weeks, 
this oil solidified into yellow crystals. To 0.9g (2.4mmol) 
of the free base in 72ml cyclohexane and 20 ml chloroform 
was added 0.98g (2.4mmol) di-£-toluyl-d-tartaric acid in 
90ml ethyl acetate. The final (+) salt fraction weighed 
approximately 300mg in the form of pure white crystals.
The salt was converted to the hydrochloride salt by 
bubbling dry HC1 through an anhydrous ether solution of 
the base.
The original mother liquor was enriched in (-)-thiorida- 
zine-di-£-toluyl-d-tartrate. To remove the remaining (+) 
salt, the solution was first roto-evaporated. The dried 
residue was mixed with 25ml cyclohexane and 150ml ethyl 
acetate while heated and stirred. Allowing this solution 
to stand at room temperature for 24hr resulted in the 
crystallization of additional (+) salt, rendering the 
mother liquor further enriched in the (.-) isomeric salt.
This organic salt solution was then roto-evaporated and
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the resulting 0.5g of residue converted to the free base, 
Basification with 5N KOH, extraction with- anhydrous ether, 
and roto-evaporation of the organic phase produced a small 
amount of (-)-thioridazine Base. Again, a portion of this 
base was converted to the hydrochloride with HC1 bubbled 
through an ether solution.
d. General Chemical Methods
Optical rotations were recorded from the free 
base form of resolved phenothiazines. All resolved 
phenothiazines were converted in part to the hydrochloride 
salt form. This was done largely to facilitate their 
dissolution in aqueous media and to provide a uniform 
acidic moiety within the pharmacological experiments. The 
purity of these hydrochloride salts was checked with 
thin-layer chromatography (silica gel G; Skelly-Solv B/ 
isopropanol, 75:25 as developing solvent; iodine vapor 
visualization). This chromatographic procedure was intended 
to detect drug decomposition products rather than exogenous 
impurities.
2. Pharmacology
a. Binding Studies
Unless otherwise specified, all binding studies 
were performed using methods developed in the laboratories 
of Solomon H. Snyder at Johns Hopkins University (Burt 
et al., '75; Creese et: al^ ., *77). The major features of 
these experiments were as follows. Freshly slaughtered
25
calves (cervical puncture) were quickly decapitated and 
their brains removed after chopping away the skull' s top, 
Following transection of the hemispheres, the anterior 
caudate was exposed along the wall of the third ventricle. 
The caudate was quickly excised and rapidly frozen with, 
dry ice or liquid nitrogen. Caudate nuclei from calf 
brains stored 1 to 25 days at -50°C were homogenized with 
the Polytron for 5 sec at a constant power setting of 
approximately 50% in 30 volumes (w/v) ice cold 50mM 
Tris HC1, pH 7.7 at 25°C (homogenizing buffer). The 
homogenate was centrifuged for 10 min at 5Q,000g in the 
preparative ultracentrifuge at 4°C. After the supernate 
was discarded, the pellet was rehomogenized for 5 sec in 
an additional 30 volumes of cold homogenizing buffer,
The homogenate was again centrifuged as before and the 
supernate fluid discarded. The final pellet was rehomo­
genized as before but in ice cold 50mM Tris buffer, pH 7.1 
at 37°C, containing IOijM pargyline, 0.1% ascorbic acid, 
120mM NaCl, 5mM KC1, lmM CaCl^ (Buffer A). The homogenate 
was then diluted with additional cold Buffer A to make a 
final 1:150 (w/v) caudate preparation, which was incubated 
at 37°C for 10 min and then returned to an ice bath.
The assay system was comprised of the following compo­
nents. Each duplicate set of incubation tubes (borosili- 
cate glass, 12x75mm) received 1.8ml caudate homogenate, 
lOOpl test drug in varying concentrations in 0.1% ascorbic
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acid, or the vehicle along (control), and 100pi of radios 
labeled agonist (3H-DA) or antagonist (spiroperidol, 3H-SP) 
in 0.1% ascorbic acid, at appropriate concentrations. Test 
drug solutions were usually prepared on the day of the 
experiment or, very rarely, stored frozen at -20°C, in 0.1% 
ascorbic acid for less than two weeks. Radioligand solutions 
were prepared on the day of use. Specific saturable radio­
ligand binding was determined by measurement of binding in 
the absence (total binding) and presence (non-specific 
binding) of the stereospecific competitor, (+)-butaclamol, 
at a concentration of lpM. The competition binding studies 
were performed using an appropriate concentration range of 
the optically active drug isomers and a radioligand con­
centration determined to approach half-maximal receptor 
saturation.
Each tube was incubated for 20 min at 37°C to attain 
equilibrium between competitor and radioligand, then the 
contents were rapidly vacuum filtered through pre-wetted 
GF/B filters, followed by three 5ml washes of ice cold 
homogenizing buffer. Filters were transferred to glass 
scintillation vials and allowed to dry overnight. After 
the addition of 10ml Aquasol, the vials were allowed to 
stand overnight to extract trapped radioactivity into the 
cocktail. The vials were then counted for 6” emissions by 
liquid scintillation spectrometry,
Scatchard analysis was performed on the saturation
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binding data (Scatchard, ’49), using disintegrations per 
minute (dpm) of the standards from the saturation studies 
and the specific binding of radioligand, For the teat 
drug experiments, activity was automatically calculated 
in terms of relative percent bound (%B), as compared to 
total binding of radioligand used in the competition studies 
as 100%B. Zero %B was defined as that activity corresponding 
to non-specific filter entrapment of radioligand from 
assay tubes with Buffer A substituted for homogenate. Per­
cent bound data were then transformed into logit units 
(Rodbard, ’74) using a programmed Monroe 1860 calculator.
Least square regression analysis between the transformed 
logit data and their corresponding competitor concentration, 
in logarithmic form, was calculated and plotted by a Hewlett- 
Packard HP 9825A desk-top computer. Raw competition data 
in counts per minute (cpm) were also subjected to computerized 
analysis of variance (ANOVA), The main effects analyzed 
were Isomers and concentrations,with duplicate analyses 
as a nested variable,
i. 3H-Dopamine Binding Experiments
Radiolabeled DA saturation studies were 
performed using five concentrations of this ligand. 
Concentrations examined were 2,5, 5, 10, 20, and 50nM 
3H-DA, All competition studies were performed with the 
concentration of 3H-DA found by Burt et al. C'75) to 
approach half maximal binding. This concentration of 5nM
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3H-DA was utilized throughout the agonist experiments,
ii. 3 H-Spiroperidol Binding Experiments
Radiolabeled SP saturation studies were 
performed with five concentrations of this ligand. The 
concentrations examined were 0,15, 0.3, 0.5, 1.0, and 
2.0nM 3H-SP. All competition studies were performed with 
the concentration of 3H-SP found by Creese et al. (’77) 
to approach half maximal binding. Throughout these 
antagonist binding competition experiments, 0.15nM 3H-SP 
was used.
b. Dopamine-stimulated Adenyl Cyclase Experiments 
Dopamine-sensitive cAMP production was assayed 
essentially as originally described by Kebabian et al.
C'72) with the modifications introduced by Clenent-Cortnier 
et al. (’75). The experiments discussed below departed 
from the original technique in the treatment of the 
neostriatal tissues during and immediately after procure­
ment. Rather than obtaining the tissues in a cold room and 
collecting the striata in a very complex nutrient buffer, 
these tissues were collected as described by Miller et al. 
(*74) and detailed below.
Rats were decapitated and their brains rapidly removed. 
Striata were quickly dissected and placed in ice cold 2mM 
Tris-maleate buffer, pH 7.4, containing 2mM EGTA (homo­
genizing buffer). Pooled striata (2 to 10 rats) were then 
homogenized in 25 volumes of fresh cold homogenizing buffer
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by 15 pestle passes in the tissue grinding tube. In one 
experiment, frozen (18 hr) calf caudate tissue was sub- 
stitued for fresh rat tissue. Homogenization was sub­
sequently carried out in all rat experiments..
The final assay mixture occupied a volume of 0.5ml.
This was comprised of 50pl test drugs at appropriate con­
centrations in 0 .1% ascorbic acid or the vehicle alone 
(0.001N HC1), 250pl buffer concentrate with additives, 
and 50ul ATP. The resulting standard assay mixture 
contained these final concentrations of the following 
substances: Tris-maleate, 80.2mM; theophylline, lOmM;
MgSO^;2.0mM; EGTA,0.6mM; ATP,0.5mM; DA, 40pM, pargyline,
10uM; ascorbic acid, 0.1%; and test drugs at various con­
centrations, Reactions were performed In triplicate by 
first adding homogenate to all solutions except ATP and 
incubating on ice for 20 min. The addition of ATP Initiated 
the reaction, which was incubated at 30°C in a shaking 
water bath for 2.5 min. Termination of reaction was 
effected by transferring the tubes to a boiling water bath 
for 2.5 min. The tubes were then centrifuged at 2000g for 
10 min to precipitate the denatured protein. Aliquots 
of 100nl were taken from each tube and diluted 1:10 in 
50 mM acetate buffer, pH 6.2, prior to analysis of cAMP of 
lOOpl aliquots by RIA. Radioimmunoassays were performed 
exactly as specified in the instructions accompanying the 
cAMP kit. Data output from the Gamma 7000 was in the form
of %B radioactivity. Comparison of these figures to a 
standard curve prepared from known amounts of cAKP allowed 
calculation of cAMP produced in the enzyme reaction under 
the influence of the resolved phenothiazine, methotrime- 
prazine. The amount of cAMP produced without stimulation 
by 40yM DA was considered basal activity, corresponding 
to 100% inhibition of stimulation. In the presence of 
40\jM DA and no competitor, maximum cAMP was produced 
(0% inhibition). The presence of various concentrations of 
resolved methotrimeprazine yielded cAMP production 
calculated in terms of % inhibition relative to the extremes 
described above.
In some experiments, modified binding studies were 
performed. The tissue preparation and reaction milieu 
was the same as that used in the enzyme assay except for 
the following: final volume, 2.0ml; no exogenous ATP was
added; 3H-DA concentrations used in these studies were 
the same as those used in the binding studies previously 
described. In these modified binding studies, the attempt 
was made to mimic conditions within the enzyme preparation. 
Homogenization was performed with the glass tube/teflon 
pestle tissue grinder, and preincubation was for 20 min 
at 0°C. Equilibrium of binding sites was allowed to occur 
during a 20 min incubation at 37°C. The receptor environ­
ment was essentially like that used in DA/AC experiments: 
Tris-maleate, 80.2mM; theophylline, 10mM; MgSO^, 2mM;
EGTA, 0.6niM; pargyline, 10uM; ascorbic acid, 0,1%; plus 
test drugs at various concentrations.
c . General Pharmacological Methods
Protein analyses' were performed on homogenates 
using the method of Lowry et al. (.'51). All standards 
(bovine serum albumin) were prepared in the same buffer 
system used in preparing the tissue homogenate undergoing 
protein analysis.
lit. RESULTS
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A. Chemistry
1. Structural Verification of P-892
Various analytical techniques were employed to con­
firm the identity of P-892. Data from some physical methods 
such as elemental analysis and mass spectrometry are pre­
sented in Table 1. The mass spectrum of P-892 is presented 
in Text-Fig. 3, The base peak of M/e 98 is consistent 
with the predicted principal fragment of P-892. This frag­
ment apparently results from a-cleavage at both nitrogen 
atoms. The NMR spectrum of P-892 is shown in Text-Fig. 4. 
Salient features of the NMR spectrum include: characteris­
tic aromatic proton signals at 6.7 to 7.45; an ABX complex 
involving the methylene group bridging phenothiazine and 
piperidine at 3.5 to 4.56; an ABX complex involving the 
methylene group bridging phenothiazine and piperidine at 
3.5 to 4.56, with coupling constants JAB=14.0 3 ^=6. 86Hz,
Jbx°6.36Hz (Dr. B. Franzus, personal communication) and the 
piperidyl methyl at 2.45.
2. Verification of Isomeric Resolution
Optical activities of resolved phenothiazines are 
given in Table 2. These rotations are specifically for the 
chemical form (base or salt) of the drug as noted in the 
table. These resolved phenothiazine derivatives were also 
checked for chemical purity by thin-layer chromatography.
Table I. 33
PHYSICAL PROPERTIES OF P-892
Elemental Analysis (HC1 salt) Calculated Observed1
% C 65.71 65.67
% H 6.62 6.87
% N 8.06 8.01
% Cl 10.23 9.90
Mass Spectrum (base) Predicted Observed
Base peak M/e 98 98
Parent peak M/e 310.47 310
Melting Point (IICl salt) 240-2°C
1 Galbraith Laboratories, Inc., Knoxville, TN 37921.
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Text-Fig. 3. Mass spectrum of purified P-892. The parent 
peak at 310 M/e and base peak at 98 M/e cor­
respond to fragmentations predicted for P-892,
Text-Fig. 4. Nuclear magnetic resonance (NMR) spectrum 
of purified P-892.
Table 2,
OPTICAL ACTIVITY OF RESOLVED PHENOTHIAZINES
Drug Isomer
Specific Rotation Specific Rotation 
Observed Literature
Thioridazine base
Dioxopromethazine base
P-892 base
Methotrimeprazine
tartrate
HCL
base
Promethazine HC1
(+)
( - )
(+)
C-)
<+>
C-)
C+)
(->
C->
(+)
{a}D° +33.0±11° Cc-l,EtOH) {«>d° +21,Q±2° (M.EtOH)1
{a>o° -37.0±3° (c=5,EtOH) {a}£° -21,0+2° (M.EtOH) 1
20
{a}j)° + 6.2±l°Cc=10,Me2CO) {a}^ + 7.0°(c=10 ,MeCO) 
{a)D° - 6.3±l°(c=20,Me2CO) {a}£° - 7,0°(c=5,Me2CO) 
{a>D° +74.0+6°(c=l.3,EtOH)
20{a>5“ -52.0+3°(c=l,EtOH)
20
ta}5" +16,9°(c=5,CHCI3)
20
{a}D +11.5°(c=10,H20)
20
{a>5“ -17.0O (c=5,CHC13)
2 5
+7.17°(c=1,H20)
^ourquin et al., C'58)
2Wunderlich et al., O'66)
3Rhone-Poulenc, personal communcation
HJindholz, (*76)
5Wyeth, Inc., personal communication
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The thin-layer chromatogram of these resolved (and some 
addition) phenothiazines is reproduced in Text-Fig, 5, All 
compounds chromatographed were in the form of hydro­
chloride salts as this form was to be used in subsequent 
pharmacological experiments. Each compound was observed 
to migrate as a single spot as the plates were developed.
B. Pharmacology
1. Binding Studies
a. General Results
The isomeric competition data graphically re­
presented are from those experiments with the highest 
overall correlation coefficients among points within the 
concentration series examined. General agreement between 
experiments with the same drug was observed, particularly 
in regard to the ratio of IC^q’s of the isomers. In all 
experiments, cmp for duplicate samples in any group typi­
cally varied 57o or less. In the measurement of radio­
activity by LSC, the amount of quenching in all samples 
was constant. This was evidenced by both uniform channel 
ratios and H#'s (Long, *77) for the samples. Counting 
efficiency was calculated to be 52.9±1.17a as determined by 
the addition of 3H-toluene as internal standard.
b. 3H-Popamine
As described in the Methods section, saturation 
data of specific dopamine receptors were calculated from 
bound counts per minute from sets of samples without (total)
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Text-Fig, 5. Thin-layer chromatogram of phenothlazine
derivatives in HC1 salt form. The compounds 
from which these samples were taken had been 
exposed to various laboratory manipulations in 
attempts to resolve the optical isomers. Only 
one iodine-vapor staining spot is seen in each 
sample of these test substances. Several of 
these substances were subsequently employed in 
pharmacological Investigations.
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and with, (non-specific) the addition of (+)-butaclaraol,
Within these sets of samples, the five concentration of 
3H-DA added varied from 2.5 to 50 nM. Total, non-specific, 
and specific binding (.the difference between total and 
non-specific) were all plotted on the same linear graph as 
a function of 3H-DA concentration. This generated typical 
curves showing saturation of specific binding as an asympto­
tic maximum is approached (Text-Fig. 6). Scatchard analysis
of the saturation data typically revealed a dissociation con-
_ 9
stant (Kjj) of 1.98 x 10 M and a maximal number of binding 
sites CB_.nv.) of 19.6 pmole/g wet weight tissue (Text-Fig. 7).lUaX
Competition studies performed with 5nM 3H-DA and various 
concentrations of isomeric phenothiazine derivatives were 
observed as per cent bound (%B) radioactivity. Sigmoidal 
curves were obtained by plotting %B 3H-DA vs. competitor 
concentration on semilog graph paper. Logit transformation 
of %B data and replotting on logit-log scales produced 
linear concentration curves. These computer-displayed plots 
are presented in figures 8 through 12, The function best 
fitting the linearized data in each plot revealed various 
values for half-maximal inhibition of 3H-DA binding (XC^q) 
by the respective isomers of phenothiazine derivatives.
These values represent the antilog of the X-intercept appear­
ing on each plot and are presented in tabular form in
Table 3. The ratios of ICcr. values for each isomer pair
jU
are also shown in this table. This estimate of receptor
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Text-Fig. 6 , Example of a 3H-DA receptor saturation study.
The filled circles represent total binding of 
radioligand at the designated concentrations. 
Open circles represent non-specific binding 
observed in the presence of lyM (+) butaclamol. 
Specific binding, shown by the filled squares, 
is the difference between total and non-specific 
binding and is seen to plateau as it approaches 
saturation. Each point represents the mean 
value of duplicate analyses.
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0.010
CORR, COEFF, - 0.9936 
slope - -5.04 x 108 
Y INT. - 0.0099
0.008
Kp = 1.98 x 
8max =0.006 PMOL
F
0.004
0.0Q2
3010 20
3H-DA SPECIFIC BINDING: PMOLES / G
Text-Fig. 7. Scatchard plot of a 3H-DA saturation study.
The abscissa represents amounts of 3H-DA 
specifically bound to striatal tissue, while 
the ordinate is the ratio of specifically 
bound over free 3H-DA. The dissociation con­
stant (K_) is the negative reciprocal slope and 
equals 2.0xl0-9M. Maximum 3H-DA binding sites 
(B„ay) are extrapolated from the X-intercept 
antPapproach 20 pmol/g wet weight caudate 
nucleus. Each point is the mean from duplicate 
analyses.
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Text-Fig. 8. Computer-graphic plot of 3H-DA competition by 
isomeric methotrimeprazine. The abscissa is 
log concentration of test drug and the ordinate 
is logit transformed binding of 3H-DA. Cor­
relation coefficients provide an estimate of 
the ideality of observed competition effects. 
The X-intercept represents the logarithm of the 
ICjq value for each isomer. Each point repre­
sents the mean value of duplicate incubations.
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Text-Fig. 9. Computer-graphic plot of 3H-DA competition by 
isomeric thioridazine(Mellaril). The abscissa 
is log concentration of test drug and the ord­
inate is logit transformed binding of 3H-DA. 
Correlation coefficients provide an estimate of 
the ideality of observed competition effects. 
The X-intercept represents the logarithm of the 
ICcq value for each isomer. Each point repre­
sents the mean value of duplicate incubations.
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Text-Fig. 10. Computer-graphic plot of 3H-DA competition by 
isomeric promethazine. The abscissa is log 
concentration of test drug and the ordinate is 
logit transformed binding of 3H-DA. Correla­
tion coefficients provide an estimate of the 
ideality of observed competition effects. The 
X-intercept represents the logarithm of the 
IC50 value for each isomer. Each point repre­
sents the mean value of duplicate incubations.
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Text-Fig. 11. Computer-graphic plot of 3H-DA competition by 
isomeric dioxopromethazine(Frothanon), The 
abscissa is log concentration of test drug and 
the ordinate is logit transformed binding of 
3H-DA. Correlation coefficients provide an 
estimate of the ideality of observed competi­
tion effects. The X-intercept represents the 
logarithm of the ICcq value for each isomer. 
Each point represents the mean value of dup­
licate incubations.
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Text-Fig, 12. Computer-graphic plot of 3H-DA competition by 
isomeric P-892. The abscissa is log concen­
tration of test drug and the ordinate is logit 
transformed binding of 3H-DA. Correlation co­
efficients provide an estimate of the ideality 
of observed competition effects, The X-inter- 
cept represents the logarithm of the XC50 for 
each isomer. Each point represents the mean 
value of duplicate incubations.
Tahle 3,
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RADIOLABELED AGONIST BINDING INHIBITION
Drug 3 H-DA
d
ICsu1
1
d/X
Methotrimeprazine 3.3x10"5 2.4x10" 6 13.75*
Thioridazine 5.0x10"6 1 .8x10"5 0.28*
Promethazine 1 .0x10"
_ 52
7.1x10
2
1.41
Dioxopromethazine 4.6xl0-14 5. SxlO"1* 0.84
P-892 2.6xl0"4 2 .8xlO“I+ 0.93
*p<0.05
1IC5o concentrations expressed In molarity (M). 
2Values given are for di-promethazine.
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stereospecificity is marked with- an asterisk if the isomeric
effect was shown to be significant (p<0.05) by comparing the
F-values and degrees of freedom from ANOVA to the upper
significance limits of the F-distribution. Under the
conditions employed in the competition studies, 3H-DA
total binding represented 1.4±0.2% (n=5) of the total
radioligand added to the assay mixture. Specific binding
was 40.5±5.1% (n=4) of the total binding with 5nM 3H-DA.
c . 3H-Spiroperidol
As described in the Methods section, specific
saturation with spiroperidol was calculated from observed
cmp from sample sets prepared without (total) and with
(non-specific) the addition of (+)-butaclamol. The
five concentrations of 3H-SP added to duplicate pairs in
each of these two sets varied from 0.15 to 2.0nM. Total,
non-specific, and their difference (specific 3H-SP binding)
were plotted on a linear graph as a function of 3H-SP
concentration. These graphs exhibited typical saturating
properties for specific binding, i.e. plateauing, as shown
in Text-Fig. 13. Scatchard analysis of typical 3H-SP
- 11
saturation data revealed a K_ of 3.2 x 10 M andD  max
of 28.7 pmoles/g wet weight of caudate nucleus tissue 
(Text-Fig. 14).
Results of competition studies performed between 
0.15nM 3H-SP and various concentrations of isomeric pheno­
thiazine derivatives were observed as %B radioactivity.
CP
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Text-Fig. 13. Example of 3H-SP receptor saturation study.
The filled circles represent total binding of 
radioligand at the designated concentrations. 
Open circles represent non-specific binding 
observed in the presence of lpM (+) butac­
lamol. Specific binding, shown by filled 
squares, is the difference between total and 
non-specific binding and is seen to plateau 
as it approaches saturation. Each point rep­
resents the mean values of duplicate analyses.
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1,0
CORR, COEFF, “ 0,9899 
SLOPE = -3,17 X 10^ 
Y INT. = 0.9110,8
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SH-SP SPECIFIC BINDING: PMOLES / G WET WT.
Text-Fig. 14. Scatchard plot of 3H-SP saturation study.
The abscissa represents amounts of 3H-SP 
bound to striatal tissue, while the ordinate 
is the ratio of specifically bound over free 
3H**SP, The dissociation constant ( K t O  is the 
negative reciprocal of the slope, 3,2xlO"llM. 
Maximum 3H-SP binding (B^x) sites are extra­
polated from the X-intercept and approach 29 
pmol/g wet weight caudate nucleus. Each point 
represents the mean from duplicate analyses.
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Linear curves were obtained by plotting logit transformed 
%B data vs. log concentration of competitor. The computer- 
drawn plots are presented in Text-Fig. 15 through. 19. The 
mathematical function best fitting the linearized data 
points revealed various values for half-maximal inhibition 
of 3H-SP binding by the respective phenothiazine isomers. 
These values are the antilogs of the X-intercept appearing 
on each plot and are presented in tabular form in Table 4. 
The ratios of the IC^q values for each pair of antipodes 
are also shown in this table. This measure of stereo- 
specificity is marked with an asterisk if the isomeric 
effect was demonstrated to be significant by ANOVA 
(p<0.05). Under the conditions employed in these compe­
tition studies, total 3H-SP binding represented 42.8+1.6% 
(n=4) of all the radioligand in the assay mixture.
Specific binding amounted to 89.4±0.6% (n=4) of the total 
3H-SP binding.
2. Enzyme Studies
Adenylate cyclase activity in rat striatal homo- 
genates was observed to be stimulated by the addition of 
exogenous DA. Addition of 40yM DA enhanced cAMP produc­
tion by 40.4+8.5% (n=3) under conditions employed in the 
enzyme assay. In two experiments studying the influence 
of (+) and (-) methotrimeprazine upon DA/AC, the mean 
stimulation of enzyme activity by DA was somewhat smaller: 
29.2%. Mean basal activity (non-stimulated activity is
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Text-Fig. 15. Computer-graphic plot of 3H-SP competition by 
isomeric methotrimeprazine. The abscissa is 
log concentration of test drug and the ordinate 
is transformed binding of 3H-SF. Correlation 
coefficients provide an estimate of the ideal­
ity of observed competition effects. The X-in- 
tercept represents the logarithm of the TCjq 
value for each isomer. Each point represents 
the mean value of duplicate incubations.
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Text-Fig. 16. Computer-graphic plot of 3H-SP competition by 
isomeric thioridazine(Mellaril). The abscissa 
is log concentration of test drug and the ord­
inate is logit transformed binding of 3H-SP. 
Correlation coefficients provide an estimate 
of the ideality of observed competition 
effects. The X-intercept represents the loga­
rithm of the IC50 value for each isomer. Each 
point represents the mean value of duplicate 
determinations.
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Text-Fig. 17. Computer-graphic plot of 3H-SP competition by 
isomeric promethazine. The abscissa is log 
concentration of test drug and the ordinate is 
logit transformed binding of 3H-SP. Correla­
tion coefficients provide an estimate of the 
ideality of observed competition effects. The 
X-intercept represents the logarithm of the 
IC50 value for each isomer. Each point repre­
sents the mean value of duplicate incubations.
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Text-Fig, 18. Computer-graphic plot of 3H-SP competition by 
isomeric dioxopromethazine(Frothanon). The 
abscissa is log concentration of test drug and 
the ordinate is logit transformed binding of 
3H-SF. Correlation coefficients provide an 
estimate of tje ideality of observed competi­
tion effects. The X-intercept represents the 
logarithm of the ICcq value for each isomer. 
Each point represents the mean value of dupli­
cate incubations.
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Text-Fig. 19. Computer-graphic plot of 3H-SF competition by
isomeric P-892. The abscissa is log concentra­
tion of test drug and the ordinate is logit 
transformed binding of 3H-SP. Correlation co­
efficients provide an estimate of the ideality 
of observed effects. The X-intercept repre­
sents the logarithm of the IC«jq value for each 
isomer. Each point represents the mean value 
of duplicate incubations.
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RADIOLABELED ANTAGONIST BINDING INHIBITION
3H-SP I C *
Drug 50 d/1
d 1
Methotrimeprazine 7.8 X io“ 6 9.5 X 10‘8 82.10*
Thioridazine 4.3 X io" 6 8.8 X
td1OH
0.49*
Promethazine 2.0 X io‘ 5 5.5 X io“ 5 2 0 .36*2
Dioxopromethazine 7.1 X 10" 5 2.6 X 10”1 0.27*
P-892 6.3 X 10'5 6.3 X 10'5 1 .00*
*p<0.05
1IC^q concentrations expressed in molarity (M). 
2Values given are for dl-promethazine.
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defined as 100% inhibition of stimulation) of 48 pmol/mg/rain 
was increased to 62 pmol/mg/min by 40uM DA C0% inhibition).. 
Any inhibition of stimulated DA/AC activity by the test 
substances was expected to fall within the ranges of 0-100%.
A plot of mean % inhibition of DA/AC as a function of 
methotrimeprazine isomer concentrations is shown in Text- 
Fig. 20. Standard errors, not shown in this figure ranged 
from 8 to 23%, resulting in no significant (p<0.05, t 
dependent) isomer effect upon DA/AC by this compound. The 
fact that no isomer effect was observed in this in vitro 
model left unanswered the question of whether the model was 
functioning as it was expected to. Demonstration of a 
concentration-dependent inhibition of activity (Miller 
et al., ’74b) would suggest that the assay was properly 
sensitive to a neuroleptic. Since there was no isomer effect 
observed, the enantiomers could be considered as a group: 
a racemate. Comparison of the grouped extremes of concen-
_ti _ 6
tration CIO to 5 x 10 M) does reveal a significant
(p<0.05, t dependent) concentration effect for this compound
considered as a racemate. The net XC^q for (+)-methotrime-
_ 8
prazine is estimated to be approximately 7 x 10 M.
Attempts at pairing binding studies with the DA/AC 
measurements failed. Binding studies using 3H-DA in the 
same homogenate medium in which DA/AC is assayed were totally 
unsuccessful. It was impossible to demonstrate specific 
3H-DA binding in either calf or rat caudate homogenates
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Text-Fig. 20. Inhibition of dopamine-stimulated adenyl cyc­
lase activity by methotrimeprazine optical 
isomers. Each point represents the mean value 
of triplicate incubations. Standard errors 
(not shown) ranged from 8 to 23% inhibition, 
resulting in no significant isomeric effect 
upon enzyme activity with methotrimeprazine. 
Overall IC^q value for (+) methotrimeprazine 
in the enzyme system is approximately 7x10 M.
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prepared in the same fashion as those for DA/AC, Since 
specific 3H-DA binding did not occur, it was impossible to 
study competition effects with test isomeric phenothiazine 
derivatives.
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IV. DISCUSSION
A. Chemistry
The objectives of the various chemical procedures under­
taken in this project were twofold. First, a relatively 
novel compound, F-892, was to be synthesized in its optically 
active Isomeric forms. Secondly, racemic thioridazine and 
dioxopromethazine were to be resolved into their dextroro­
tatory and levorotatory isomers. These goals were ultimate­
ly achieved.
On the basis of the qualitative organic analyses per­
formed upon P-892, it appears correct to state that this 
compound has indeed been synthesized, Observed specific 
rotations indicate that it has also been resolved into 
optical isomers. Since there is no reference in the chemical 
literature to this compound, there are no means of comparing 
it to accepted criteria of chemical or optical purity. 
Chemical purity Is apparently quite good, as only a single 
substance is observed in analytical thin-layer chromato­
graphy and NMR spectroscopy (Warren et: ai. , '66). In 
addition, the mass spectral and elemental analysis data do 
not suggest the presence of any contaminating material.
The question of the extent of optical purity in the resolved 
P-892 isomers remains unanswered. The difference between 
the observed rotations of the two isomers (Table 2) suggests 
that the C+) isomer is better resolved. It may be possible
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that errors in the relatively subjective measure of specific 
rotation (obtained with the very small amounts of these 
isomers- available) may have contributed to this difference, 
Nevertheless, the large specific rotations observed do 
indicate attainment of resolution (Table 2).
The other compounds were also appreciably resolved into 
their antipodes. Comparison of observed rotations to the 
literature values for thioridazine and dioxopromethazine 
enantiomers indicates that they approach or exceed published 
values (Table 2). Because semi-micro scale quantities of 
these compounds were used in making the subjective rotation 
measurements, departures from published values are probably 
due to observational errors. Verification and objective 
quantification of the degree of optical resolution effected 
with these drugs would require an additional analytical 
procedure. Nuclear magnetic resonance spectroscopy employing 
a chiral shift reagent could provide an estimate of optical 
purity in these samples (Kime and Sievers, '77). As the 
equipment has not been available for performing this ancillary 
analysis on milligram size samples, optical rotation data 
must suffice for demonstrating isomeric resolution. Based 
upon rotation data, then, one may conclude that all drugs 
used in the pharmacological studies were resolved to a 
relatively high degree of optical purity.
Chemical purity of thioridazine HC1 and dioxoprometha­
zine HC1 was also readily demonstrated. After the many
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manipulations required to separate their isomers, contamina­
tion might have been anticipated. Analytical thin-layer 
chromatography demonstrated that only one pure substance 
was contained in each sample of the resolved isomers. The 
other compounds shown in Text-Fig. 5 were initially planned 
for pharmacological evaluation but were subsequently omitted. 
Their deletion was due to the fact that neither oxomemazine 
HC1 nor I-HC1 (P-892 rearrangement compound) were, in fact, 
successfully resolved into optical isomers. Resolution 
of racemic bases into enantiomers is a completely empirical 
technique. Methods which are successful with one compound 
are not, as a rule, successful with another. Due to the 
difficulty of working with only one resolving agent and 
milligram quantities of oxomemazine and compound I, attempts 
at resolution failed after several weeks of work and further 
attempts were abandoned.
B. Pharmacology
1. Binding Studies
a. General Considerations
i. Saturation Studies
A basic supposition in these experiments was 
that radioligand binding was indeed specific and saturable 
and that the number of these binding sites was approximately 
equal for both agonists and antagonists. Evidence for this 
conclusion had been presented earlier by Burt et al. C'75) 
and Creese et al^ C'77) for 3H-DA and 3H-SP respectively.
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While a report by Briley and Langer C'78) indicated two
binding sites for 3H-SP in rat caudate nucleus, this
apparently is not the situation in calf caudate ( C r e e s e
et al., ’77). The data obtained from the saturation
studies do indicate that the numbers of binding sites for
3H-DA and 3H-SP are quite similar (Text-Fig. 7 and 14).
Furthermore, the B values are in essential agreementmax
with those reported in the literature (Burt et al., *75; 
Creese et al., '77) for the respective radioligands. The 
use of 3H-SP as a model labeled antagonist had been found 
to be highly advantageous (Leysen et al., ’78) for in vitro 
binding studies. This situation appeared to prevail in 
these experiments as well. Specific binding curves for 
each ligand were observed to be similar in all experiments 
employing the standard conditions described in the Methods 
section and used in the competition studies. It was 
concluded, therefore, that the two binding assays were 
functioning optimally. Furthermore, it was concluded that 
competition studies would render data relevant to previous 
observations and consistent with postulates formulated 
upon these in vitro models.
ii. Competition Studies
It is clear that optical isomers of some 
phenothiazine derivatives do have differential effects 
upon both agonist and antagonist dopaminergic radioligand 
binding. The observed effects of these enantiomers, in
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competition with labeled DA and SP, suggest several 
properties attributable to their receptors. Two trends 
are discernable in the overall data from binding competition 
experiments, The first of these is that the difference 
between isomeric effects (ratio of (+) and (r) ^ 5 0  
values) is, in general, greater for those compounds with the 
smaller IC^q's. This observation is in keeping with 
Pfieffer's postulate ('56); the more potent a competitor 
is at displacing the radioligand, the greater is its 
ratio of isomeric effects. A logical refinement of this 
postulate suggests an even more broad-based conclusion.
As Ariens et al.(r79) explain, if the asymmetric center 
of a functionality does markedly influence pharmacological 
effects, that functionality is then a critical element 
in receptor interaction. As previously mentioned, the 
chemical nature of the 10-N substituent (Text-Fig. 2) has 
been strongly implicated in phenothiazine antipsychotic 
effects (Gordon et al., '63; Fenner, ’70). The in vitro 
observations described in this text do substantiate the 
concept of direct involvement of the 10-N-alkyl func­
tionality in phenothiazine/receptor interactions. There 
are two interesting aspects of this phenomenon apparent 
from the binding data. Both methotrimeprazine and thiori­
dazine possess the optimum antischizophrenic three-carbon 
chain between the 10-N and the terminal tertiary amino 
group. Methotrimeprazine contains its asymmetric carbon
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at the 2 position, while thioridazine's is at the 3 
position and is distinguished by less rotational freedom 
due to its location in the piperidine heterocyclic 
ring structure (Text-Fig. 2). In the 2 position, a greater 
isomeric effect is observed than in the 3 position. Further­
more, an inversion of optical activity corresponding to the 
isomer with greater displacing ability (and presumably 
greater receptor affinity) is seen as the asymmetric carbon 
is moved to the 3 position. More generally, this is the 
observed situation when the asymmetric center is next to 
the terminal amino group. This is the case in thioridazine 
competition with 3H-DA and 3H-SP, while it is seen only in 
3H-SP displacement by promethazine and dioxopromethazine.
This will be elaborated upon in a later section.
This brings us to the second major fact obtained from 
the binding studies as a group. In keeping with previous 
reports (Creese et al., ’75b), antagonists (such as the 
phenothiazine derivatives studied in these experiments) 
displace antagonists (3H-SP) better than they displace 
agonists (3H-DA). This is evidenced by the correspondingly 
smaller value of the more potent isomer (or equipotent
isomer) for 3H-SP competition compared to 3H-DA. This 
observation was a keystone of the two-state receptor theory. 
These experimental data support this theory on the basis 
of similar observations, yet surpass the previous indirect 
evidence, There is a large difference observed in stereo-
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specificity (ratios of 1C,-q values between (+) and X~) 
isomers) between 3H-DA and 3R-SP binding. Differences 
are seen in comparison of isomeric stereospecificity for 
all drugs tested except P-892, a compound with no discerna- 
ble CNS effects (Hieschulz et al. , '56, ’59). This ob­
servation is compatible with both the two-state or the two- 
distinct receptor models. A two-state receptor could 
theoretically change conformation to such an extent that 
stereospecific recognition of a test antagonist would be 
markedly altered. Two distinct receptors would, by de­
finition, possess different stereospecificities. The data 
obtained from the binding competition studies are clearly 
incompatible with the notion that 3H-DA and 3H-SP bind to 
an identical recognition site. This conclusion is also 
supported by a recent thermodynamics analysis of agonist 
and antagonist binding (Lew and Goldstein, ’79).
Ariens et al. C'79) have proposed an interesting model 
of recognition sites on receptors. Their concept of a 
receptor is based upon physico-chemical observations and 
theories which include similar phenomena as those observed 
in these experiments. As a rule, antagonists are larger 
and more hydrophobic than agonists. Hydrophilic agonists 
are envisioned as interacting with relatively hydrophilic 
regions on a membrane such as an externally oriented protein 
region. The interface between this protein and surrounding 
lipid molecules would comprise an accessory binding site
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that would accomodate antagonists. This interface would 
be a highly ordered set of atoms, almost crystalline in 
nature. If a hydrophobic region of an antagonist inter­
acted with a lipid/protein interface, a high degree of 
stereospecificity might be expected, A situation such as 
this is dramatically evident in 3H-DA and 3H-SP binding 
competition with (+) and (-)-methotrimeprazine. It can 
be seen from Tables 3 and 4 that the stereospecificity of 
the 3H-SP receptor is roughly six times that of the 3H-DA 
receptor.
b . 3H-Dopamine Binding Competition
The salient point in the experiments with 
3H-DA displacement is that an isomeric effect is seen only 
with methotrimeprazine and thioridazine. These are the 
two drugs in this study with clinically useful neuroleptic 
actions. In contrast, promethazine, dioxopromethazine, and 
P-892 are devoid of clinically useful antipsychotic effects, 
and all fail to exhibit a stereospecific interaction with 
the 3H-DA recognition site (Table 3). These compounds 
are not well discriminated by the receptor, as millimolar 
concentrations are required to displace half of 3H-DA 
binding. The recognition site for 3H-DA is only able to 
discriminate between configurations of compounds with the 
highest affinities and intrinsic neuroleptic actions.
c, 3H-Spiroperidol Binding Competition
The recognition site for 3H-SP is capable of
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differentiating between configurations of many phenothia- 
zine derivatives (Table 4). Since this site has a high 
order of stereospecificity which exceeds the boundary of 
neuroleptic effects, the "antagonistic site” may be pharma­
cologically differentiable from the "neuroleptic site".
While promethazine is not a clinically useful neuroleptic and 
has no stereospecific effect on 3H-DA binding, its (+) 
isomer is approximately twice as effective as the racemate 
in displacing 3H-SP. Interestingly, promethazine is 
capable of inducing extrapyramidal side effects which are 
also general characteristics of phenothiazine neuroleptics 
(Wade, *77). This suggests, perhaps, a potentiality for 
discriminating between neuroleptic effects and "antagonist 
site" effects (e.g. Parkinsonism) in drug design.
A comment is in order concerning the isomeric effects 
of P-892. While ANOVA suggests a significant differential 
effect upon 3H-SP binding with C+) and (-)-P-892 at the 
95% confidence level, this is not realistic. The signifi­
cant difference between these two isomers is solely a 
product of the exceptional reproducibility within duplicate 
samples at each concentration of these competitors. Repro­
ducibility was generally better in 3H-SP experiments than 
in those with 3H-DA, but with P-892, variation between 
duplicates was on the order of 1%. The more realistic 
check upon isomeric effects, the ratio of (+) to (-) 
values, demonstrates the actual equivalence of these two
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configurations of P-892, A ratio equal to or near a value 
of 1.0 indicates equipotence in pharmacological action, 
d. Isomeric Drug Effects
It is apparent from the experimental data 
that neuroleptic effects of some clinically employed agents 
are influenced by their optical isomers. Thioridazine is 
one such drug. If this medication were administered in the 
dextrorotatory form, optimal antischizophrenic effects 
might be obtained at lower overall dosage. When one 
examines a plot of in vivo neuroleptic dose vs in vitro 
response by Seeman et al. (.'76a), it is apparent that thiori­
dazine departs the most from an otherwise excellent corre­
lation. Racemic thioridazine is also the only optically 
active agent included on this graph. Since only a portion 
of the racemic dose is actually effective in controlling 
schizophrenia, a plot of the active (+) isomer dose vs. 
its effect should more closely correspond to the general 
correlation seen withotherneuroleptics of all classes.
The data suggests that (-)-methotrimeprazine may be 
a highly potent neuroleptic. While this compound is used in 
Europe, it is not approved for use as a neuroleptic in 
the United States. Currently, (-)-methotrimeprazine is 
indicated for use in this country only as an analgesic.
The relatively high doses used for analgesia produce marked 
hypotension as an adverse effect. With the apparently low 
doses of this drug necessary to ameliorate schizophrenic
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symptoms, this side effect may be negligible.
2. Enzyme Assay
The effects of methotrimeprazine upon DA/AC were 
in marked contrast to those in the binding studies. Where 
(.-)-methotrimeprazine was much more effective at inhibiting 
both 3H-DA and 3H-SP binding in the calf caudate preparation 
(Tables 3 and 4), no significant isomeric effect was seen 
in rat DA/AC. The DA/AC model of dopaminergic systems 
appears to lack stereospecificity at the receptor recogni­
tion site for this neuroleptic. If one assumes that the 
intrinsic nature of rat and calf radioligand binding sites 
are the same (.Burt et al. , '75) and that both in vitro 
systems approximate physiological!! reality, then it is possi­
ble to conclude that the recognition sites for DA/AC and 
3H-DA binding are different.
This conclusion must be considered in light of data from 
the ancillary binding studies which were coupled to the 
DA/AC experiments. It was impossible to demonstrate 
specific saturable binding of 3H-DA within the conditions 
used for the enzyme assay. This situation prevailed with 
both fresh rat caudate homogenates and frozen calf caudate 
nucleus homogenates. The fact that the type and molarity 
of the buffer system required for maximal enzyme activity 
was quite different from that employed in the binding 
studies may be postulated to alter the conformation of the 
receptor site. This is a commonly recognized phenomenon
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in enzymological studies and there is evidence that the 
DA receptor is proteinaceous in nature (Breton eh al. , * 77) , 
Overall, it is difficult to reconcile the differences in 
methodology between the DA/AC and radioligand binding in 
vitro models. Methodological differences make conclusions 
regarding the identity of the receptors in question diffi­
cult to defend on a logical basis. Postulates regarding 
the relationship between DA/AC and radioligand binding sites 
as presented by Creese et al. C’79) must be considered as 
highly speculative. The fact that drug specificity at 
radio-agonist binding sites more closely resembles DA/AC 
drug sensitivity than does radio-antagonist binding specifi­
city may actually be an experimental artifact.
3. Further Research
a. Binding Studies
The observation that (-)-methotrimeprazine and 
(+)-thioridazine are the more potent isomers in displacing 
both 3H-DA and 3H-SF is an interesting point. As noted 
previously, the salient structural differences between these 
drugs is the location of the asymmetric carbon in either 
a 2-propyl or 2-piperidyl position, respectively. The 
difference in rotation of the most active agent itself is 
of interest, but the absolute magniturde of differences in 
isomeric effects (stereospecificity) is of note, too. It 
is possible that the distance between the terminal amino 
function and the asymmetric center is a critical parameter
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influencing drug/receptor interaction. If this is the 
prevailing situation, the magnitude of isomeric differences 
could serve as an index of significance for particular 
orientations (both distance and angle) of substituents added 
to phenothiazine (or other heterocyclic systems) in design­
ing neuroleptic drugs. Asymmetry may serve as a high reso­
lution probe of geometric interaction of various neuroleptic 
compounds with their target receptors. If many of the op­
tically active phenothiazines available could be obtained 
in their enantiomeric forms, more refined studies of 
receptor topology has been presented previously (Miller 
et al., '74a; Clement-Cormier et al., *79) with much more 
restrictive pharmacological probes. Actually analyzing recep­
tor topography could have implications for designing more 
efficacious drugs. It might ultimately be possible to 
tailor an antagonist for the particular target receptor that 
antidopaminergic side effects such as Parkinsonism would be 
removed from the spectrum of neuroleptic effects (Kukla 
et al., ’79).
It must be remembered that these in vitro binding studies 
have largely focused upon the basal ganglia. This is most 
likely due to the fact that there is rich dopaminergic 
innervation in the striatum. It is highly probably that 
the disruption In dopaminergic function presumed to cause 
schizophrenic manifestations is located in other brain 
regions. A recent report by Bird et al. (*79) suggests that
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the nucleus accumbens may actually be the site of biochemi­
cal alteration in schizophrenia. It may be a reasonable 
extension of in vitro studies to examine dopaminergic 
receptor characteristics in other brain areas such as the 
nucleus accumbens.
b . Enzyme Studies
The studies with DA/AC reported in this text 
must be considered preliminary. Additional experiments are 
required to characterize more precisely the influence of 
enantiomers upon this in vitro dopaminergic system. A 
recent report (Clement-Cormier ejt al,, *79) dealing with the 
optical isomeric effects of alkaloids containing a rigid 
DA pharmacophore upon DA/AC does indicate a differential 
inhibition by this class of drugs.
Regardless of the ultimate degree in technical resolu­
tion of the enantiomeric influences upon DA/AC, a frustra­
ting question will persist. Since the in vitro models of 
3H-DA binding and DA/AC are incompatible and each subjects 
the receptors to different environments, a novel approach 
must be taken before these models can be appropriately 
compared. Until such a technological break-through is 
obtained, the relationship between these two systems will 
remain an enigma.
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